Abbott: Schizophrenia trials

The registry lists 12 Schizophrenia studies with Abbott as lead sponsor. 0 are open to participants now and 0 have results posted.

Phase 1 2Phase 2 5Phase 3 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Positron Emission Tomography Study of SLV354 in Healthy Subjects and Subjects With SchizophreniaCompletedNCT01545310Phase 1
• Pharmacokinetic Study of ABT-126 in Stable Subjects With SchizophreniaCompletedNCT01043458Phase 1
• An Evaluation of the Safety and Efficacy of ABT-925 in Subjects With Acute Exacerbation of SchizophreniaTerminatedNCT00412620Phase 2
• Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenic PatientsTerminatedNCT00396214Phase 3
• Switch Study of Existing Atypical Antipsychotics to BifeprunoxCompletedNCT00347425Phase 3
• Patient-reported Outcomes in the Treatment of SchizophreniaCompletedNCT00230828Phase 3
• Bifeprunox in the Treatment of SchizophreniaCompletedNCT00193713Phase 3
• Bifeprunox in the Treatment of SchizophreniaCompletedNCT00193687Phase 3
• To Evaluate the Impact of Treatment Interruption on Re-initiation of BifeprunoxCompletedNCT00141479Phase 2
• Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Schizophrenia or Bipolar DisorderCompletedNCT00139919Phase 2
• Twice Daily Titration Study of Bifeprunox in Subjects With SchizophreniaCompletedNCT00139906Phase 2
• Depakote ER Plus an Atypical Antipsychotic Vs. an Atypical Antipsychotic Alone in the Treatment of SchizophreniaCompletedNCT00073164Phase 2